First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors

Funda Meric-Bernstam; Do-Youn Oh; Yoichi Naito; Toshio Shimizu; Vincent Chung; Haeseong Park; Stephanie Gaillard; Fujun Wang; Zachary A Cooper; Krista Kinneer; Marlon Rebelatto; Lyndon Kirby; Nadia Luheshi; Neil Miller; Andreea Varga; Linda R Mileshkin

Conference Proceedings

First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors

Funda Meric-Bernstam, Do-Youn Oh, Yoichi Naito, Toshio Shimizu, Vincent Chung, Haeseong Park, Stephanie Gaillard, Fujun Wang, Zachary A Cooper, Krista Kinneer, Marlon Rebelatto, Lyndon Kirby, Nadia Luheshi, Neil Miller, Andreea Varga, Linda R Mileshkin

JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2022

DOI: 10.1200/jco.2022.40.16_suppl.tps3153

Abstract

TPS3153 Background: ADCs are a class of anti-cancer agents that leverage the selectivity of monoclonal antibodies to preferentially target and deliver chemotherapeutic agents to cancer cells. AZD8205 is an ADC, administered by IV infusion, that consists of a human anti-B7-H4 antibody conjugated via a cleavable linker to a topoisomerase I inhibitor (TOP1i) warhead. B7-H4 is a transmembrane protein that binds to an unknown receptor on activated T cells, inhibiting their function. It is highly expressed by a wide variety of tumors including cholangiocarcinoma (CCA) and breast, ovarian and endometrial cancers, and is associated with poor prognosis. AZD8205 specifically binds to B7-H4 expressing..

View full abstract